Literature DB >> 10839756

Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection.

A D Murdin1, P Dunn, R Sodoyer, J Wang, J Caterini, R C Brunham, L Aujame, R Oomen.   

Abstract

Chlamydia pneumoniae is emerging as a significant human pathogen. Infection causes a range of respiratory tract diseases and is associated with atherosclerosis. A vaccine could provide a considerable public health benefit; however, antigens able to elicit a protective immune response are largely unknown. A panel of open-reading frames (ORFs) from the C. pneumoniae genome sequence was screened for ability to elicit protective responses. Balb/c mice immunized with DNA containing the ORFs were tested for their ability to limit lung infection following an intranasal challenge. Immunization with DNA encoding the major outer membrane protein or an ADP/ATP translocase (Npt1(Cp)) of C. pneumoniae resulted in a reduced bacteria load in the lung after challenge. The identification of these antigens as protective is a significant step toward development of a C. pneumoniae vaccine and demonstrates the feasibility of using a DNA immunization strategy to screen the C. pneumoniae genome for other protective ORFs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10839756     DOI: 10.1086/315605

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

Review 1.  Chlamydial infection in sheep: immune control versus fetal pathology.

Authors:  G Entrican; D Buxton; D Longbottom
Journal:  J R Soc Med       Date:  2001-06       Impact factor: 5.344

2.  Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses.

Authors:  Z Dong-Ji; X Yang; C Shen; H Lu; A Murdin; R C Brunham
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

3.  Adjuvant modulation of the immune responses and the outcome of infection with Chlamydia pneumoniae.

Authors:  L Bandholtz; M R Kreuger; C Svanholm; H Wigzell; M E Rottenberg
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

4.  Detection of Chlamydia pneumoniae-specific antibodies binding to the VD2 and VD3 regions of the major outer membrane protein.

Authors:  Marcus Klein; Arne Kötz; Katussevani Bernardo; Martin Krönke
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

5.  Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines.

Authors:  Qing He; Luis Martinez-Sobrido; Francis O Eko; Peter Palese; Adolfo Garcia-Sastre; Deborah Lyn; Daniel Okenu; Claudiu Bandea; Godwin A Ananaba; Carolyn M Black; Joseph U Igietseme
Journal:  Immunology       Date:  2007-04-23       Impact factor: 7.397

Review 6.  Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles.

Authors:  Rajnish Sahu; Richa Verma; Saurabh Dixit; Joseph U Igietseme; Carolyn M Black; Skyla Duncan; Shree R Singh; Vida A Dennis
Journal:  Expert Rev Vaccines       Date:  2018-02-06       Impact factor: 5.217

7.  Novel Chlamydia pneumoniae vaccine candidates confirmed by Th1-enhanced genetic immunization.

Authors:  Yihang Li; Sudhir K Ahluwalia; Alexandre Borovkov; Andrey Loskutov; Chengming Wang; Dongya Gao; Anil Poudel; Kathryn F Sykes; Bernhard Kaltenboeck
Journal:  Vaccine       Date:  2009-12-02       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.